Skip to main content
. 2019 Oct 10;18(6):5905–5916. doi: 10.3892/ol.2019.10977

Figure 3.

Figure 3.

(A) Calibration curve of the nomogram for predicting the 3-year OS rates of patients with stage II and III NSCLC from the validation set. (B) Calibration curve of the nomogram for predicting the 5-year OS rates of patients with stage II and III NSCLC from the validation set. OS, overall survival; NSCLC, non-small cell lung cancer.